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OBJECTIVES This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin
as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early
reperfusion, recurrent ischemia and patency at 24 h.
BACKGROUND Low-molecular-weight heparin, given subcutaneously twice daily without monitoring, might
be an attractive alternative to conventional intravenous heparin in the treatment of acute
myocardial infarction.
METHODS In 101 patients dalteparin/placebo 100 IU/kg was given just before streptokinase and a second
injection 120 IU/kg after 12 h. Monitoring with continuous vector-ECG was done to obtain
signs of early reperfusion and later ischemic episodes. Blood samples for myoglobin were
obtained at start and after 90 min to evaluate signs of reperfusion. Coronary angiography was
performed after 20–28 h to evaluate TIMI-flow in the infarct-related artery.
RESULTS Dalteparin added to streptokinase tended to provide a higher rate of TIMI grade 3 flow in
infarct-related artery compared to placebo, 68% versus 51% (p 5 0.10). Dalteparin had no
effects on noninvasive signs of early reperfusion. In patients with signs of early reperfusion,
there seemed to be a higher rate of TIMI grade 3 flow, 74% versus 46% (myoglobin) (p 5
0.04) and 73% versus 52% (vector-ECG) (p 5 0.11). Ischemic episodes 6–24 h. after start
of treatment were fewer in the dalteparin group, 16% versus 38% (p 5 0.04).
CONCLUSIONS When dalteparin was added as an adjuvant to streptokinase and aspirin, there were tendencies
for less ECG monitoring evidence of recurrent ischemia and better patency at 24 h,
warranting further study. (J Am Coll Cardiol 1999;33:627–33) © 1999 by the American
College of Cardiology
Since 1988 intravenous thrombolysis is routinely used in the
treatment of acute myocardial infarction. Early successful
reperfusion and maintained patency of the infarct-related
artery reduces the size of the myocardial infarction, risk of
cardiac insufficiency and mortality (1,2). The best results are
obtained in patients treated within the first hours after onset
of symptoms and with early complete restoration of flow
(TIMI3) in the infarct-related artery (3,4). Only patients
without reocclusion and maintained Thrombolysis in Myocar-
dial Infarction Trial (TIMI) grade 3 flow in the infarct-related
artery have a long-term favorable effect of thrombolysis (5–7).
The additional effect of aspirin as treatment of acute
myocardial infarction is today a well-established standard
therapy (8,9). Heparin infusion after treatment with throm-
bolytic agents improves early patency in the infarct-related
artery (10). However, the influences of heparin on long-
term mortality is less clear (11–13). In clinical practice,
heparin infusions monitored by activated partial thrombo-
plastin time (aptt) are cumbersome and the value of aptt is
reduced (14). Low-molecular-weight (lmw) heparin as an
adjuvant to thrombolytic treatment might be an alternative
to standard intravenous heparin as it is simpler to adminis-
trate and it can be given as a subcutaneous weight adjusted
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twice daily standard dose without monitoring (15,16).
Therefore this treatment might be used for a longer period of
time until passivation of the infarct-related coronary lesions.
In a pilot study we have investigated whether subcutane-
ous lmw-heparin added to streptokinase and aspirin is safe
and if it improves patency and maintains TIMI grade 3 flow
in infarct-related coronary arteries. We also investigated
whether lmw-heparin influences postthrombolytic ischemic
episodes.
PATIENTS AND METHODS
Design. This study was a prospective, multicenter, double
blind, randomized and parallel-group trial. The primary aim
was to investigate if dalteparin (Fragmin, Pharmacia &
Upjohn, Stockholm, Sweden) has additional effects to
conventional thrombolytic therapy with streptokinase on
blood flow in infarct-related coronary arteries 20–28 h after
start of thrombolytic treatment. Secondary aims were safety
and the effects of dalteparin regarding occurrence of signs of
early reperfusion and postreperfusion ischemic episodes as
indicated with biochemical markers (myoglobin) and con-
tinuous vector-ECG. Other secondary aims were to evalu-
ate the effects of dalteparin in patients with noninvasive
signs of early reperfusion regarding the rate of TIMI grade 3
flow in the infarct-related arteries and postreperfusion ischemic
episodes.
Patients. The patients were recruited at three Swedish
hospitals between May 1993 and May 1995. Patients
admitted to the Coronary Care Units with chest pain during
the last 12 hours suggesting acute myocardial infarction
with ST-elevation or new or previously unknown left bundle
branch block were eligible for inclusion in this study.
Exclusion criteria were conditions with an increased risk
of bleeding; contraindication to streptokinase; ongoing
treatment with heparin or lmw-heparin; any condition that
made early coronary angiography or early revascularization
unsuitable or contraindicated; previous coronary artery by-
pass surgery; aortic stenosis with hemodynamic importance;
increased risk for embolization; known renal (creatinine
.200 umol/L) or liver insufficiency (prothrombin time
,50% of normal); age over 80; previous inclusion in this
study or participation in another study.
Written and oral information was given, and witnessed
consent was obtained before inclusion. The study was
approved by the ethics committees of both participating
university hospitals and by the Swedish Medical Products
Agency. All procedures followed the Declaration of Helsinki.
Randomization and the study drug. The randomization
was done in blocks within each center. The first injection of
the study drug dalteparin/placebo was given just before the
start of thrombolysis, 100 U/kg subcutaneously. A second
subcutaneous injection of 120 U/kg was given 12 h later. No
further dose of dalteparin was given after evaluation of
primary endpoint by coronary angiography. Maximum dose
at each occasion was 10000 U.
Additional drugs. Patients previously on aspirin continued
on 75 mg orally daily. Patients not previously on aspirin
were given 300 mg as an oral bolus and thereafter 75 mg
orally daily. Immediately after the injection of dalteparin/
placebo, streptokinase was given intravenously as 1.5 million
Units infusion during 60 min. Nitroglycerin infusion was
started during or early after streptokinase infusion unless
contraindicated and continued for at least 24 h, until and
during the coronary angiography. Beta-receptor blockers,
ACE-inhibitors, Calcium channel inhibitors and other drugs
were given at the discretion of the responsible physician.
Vector-ECG. Immediately after the start of treatment,
monitoring with continuous vector-ECG was started and
continued until the coronary angiography was done after
20–28 h. Vector-ECG was recorded by the 8 lead MIDA-
system (Ortivus). The recordings were stored on diskettes
and evaluated by two external experts without any knowl-
edge of patient’s characteristics and randomization. A re-
duction of ST vector magnitude (STVM), .50% if STVM
was .200 uV during the initial 120 min or a reduction of
STVM .25% if STVM was 100–200 uV from the start,
was regarded as indicator of early reperfusion (17). Ischemic
episodes were defined as a reversible increase of STVM
.50 uV from the patient’s own baseline for .1 min (18).
Blood samples. Blood samples including myoglobin were
obtained just prior the start of treatment and after 90 min.
Myoglobin was analyzed by a radioimmunoassay (19). A
relative increase of myoglobin T90-TO/TO .4 (20) or a
slope of increase of myoglobin .150 ug/L/h (21) were
taken as signs of reperfusion.
Coronary angiography. Coronary angiography was per-
formed 20–28 h after inclusion and 8–16 h after the last
injection of the study drug. Five respectively three standard-
ized projections of the left and right coronary arteries were
used and recorded with 35 mm cinefilm. The evaluation was
made retrospectively by consensus of two radiologists with-
out knowledge of the randomized groups. The primary
efficacy variable was TIMI grade in the infarct-related artery
which was identified in relation to ECG-changes.
Safety. Major bleeding was defined as a decrease in the
hemoglobin level of .20 g/L in connection with clinical
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
GUSTO 5 Global Utilization of Streptokinase and
t-PA for Occluded Arteries
Lmw-heparin 5 low-molecular-weight heparin
PTCA 5 percutaneous coronary angioplasty
STVM 5 ST vector magnitude
TIMI 5 Thrombolysis In Myocardial Infarction
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symptoms, need of transfusion of blood, muscle or joint
bleeding, intracranial bleeding, interruption of treatment
because of bleeding or death caused by bleeding. Minor
bleeding was defined as a decrease in the hemoglobin level
of .20 g/L without signs of bleeding or any bleeding that
did not meet any of the criteria for major bleeding.
Clinical events and follow up. Recorded clinical events
were death, myocardial reinfarction or revascularization.
Myocardial infarction was defined according to WHO
criteria. Revascularization, percutaneous coronary angio-
plasty (PTCA) or coronary artery bypass grafting (CABG)
was only performed if there was spontaneous or exercise
induced ischemia.
Each patient stayed in hospital during the acute phase.
The study treatment was only given twice (until the coro-
nary angiography). The patients had a final follow-up visit
after 14–21 days.
Statistics. All randomized patients were included in the
evaluation of safety and clinical events. The evaluation of
the differences in the TIMI grade 3 flow could obviously
only be analyzed in patients with coronary angiograms.
Conventional chi-square tests were used to compare the
treatment groups. In cases with less than five expected in
any cells, Fischer test was used to evaluate significances. P
values less than 0.05 in two tailed tests were considered to
indicate significance.
RESULTS
One hundred one patients, 71 males and 30 females were
included in the study. The median age was 67 years (37–78).
There were some (nonsignificant) differences in the baseline
characteristic between the dalteparin-treated (54) and the
placebo-treated (47) groups in this small material (Table 1).
Coronary angiography was performed in 93 of 101 patients
and 56 patients had TIMI grade 3 flow, 16 grade 2 flow, 1
grade 1 flow and 20 grade 0 flow in the infarct-related artery
after 20–28 h. Of the eight patients without coronary
angiography, three died before the planned investigation (all
3 from the placebo group), and five had contraindications.
Myoglobin levels were analyzed in 97 patients. Adequate
vector-ECG recordings were obtained in 76 patients. In the
other 25 patients, recordings were either inadequate (n 5 5)
or not performed for various reasons.
Dalteparin added to streptokinase and aspirin had no
effect on the noninvasive indicators of early reperfusion,
evaluated by the rise of myoglobin during 90 min or the
regression of ST-elevation at vector-ECG during 120 min
(Table 2).
Concerning the primary aim, the dalteparin group tended
to have a higher rate of TIMI grade 3 flow in the
infarct-related arteries at the time of coronary angiography
(Table 3). Assuming that the three patients who died before
the scheduled angiogram had TIMI grade 0-1 flow, there
would be a significant (p 5 0.045) difference between the
groups. In patients with signs of early reperfusion based on
myoglobin, there was a significantly higher rate of TIMI
grade 3 flow after 20–28 h in the infarct-related arteries in
the dalteparin group compared with the placebo group
(Table 3). Also in patients with vector-ECG signs of early
reperfusion, there tended to be a higher frequency of TIMI
grade 3 flow in the infarct-related arteries in the dalteparin
group but the difference was not significant (Table 3).
The rate of patients with postthrombolytic ischemic
episodes registered on vector-ECG the first 24 h after the
thrombolytic treatment tended to be lower in the dalteparin
group compared with the placebo group. Excluding the
initial 6 h of unstable coronary blood flow early after
thrombolysis, the rate of ischemic episodes was significantly
lower in the dalteparin group and especially in patients with
vector-ECG signs of early reperfusion (Table 4).
Clinical outcome and safety. There was no significant
difference in clinical outcome between the two groups.
There were no cerebral bleedings. Five of the six bleedings
occurred in the dalteparin group and most of them were
minor (hematoma related to the puncture sites in the
femoral arteries). There were more reinfarctions in the
dalteparin group and five of eight occurred between
24–72 h after termination of dalteparin. Regarding deaths
and revascularization, there were no differences (Table 5).
Table 1. Baseline Characteristics
Placebo
n 5 47
Dalteparin
n 5 54
Patients Characteristics
Male 77 65
Age (years) 64 (41–78) 68 (54–77)
Body weight (kg) 78 (55–130) 78 (51–104)
Risk Factors %
Current smoker 30 35
Hypertension 36 18
Dyspnea 13 11
Diabetes mellitus 13 7
Previous myocardial infarction 11 17
Angina .1 month 23 22
Chest pain during the last 24 h 34 32
UAP ,1 month 36 30
Medication At Entry %
Aspirin 19 13
Betablockers 26 11
Digitalis 8 2
ACE-Inhibitors 14 2
Diuretics 19 15
Calcium Antagonists 19 13
Nitrates 11 9
Medication at Follow up %
Aspirin 88 92
Lipid Lowers 5 4
Betablockers 85 88
ACE-Inhibitors 24 40
Nitrates 17 12
629JACC Vol. 33, No. 3, 1999 Frostfeldt et al.
March 1, 1999:627–33 Lmw-heparin as Adjuvant to Thrombolysis in Acute MI
DISCUSSION
This is the first study that evaluates the influence of
lmw-heparin in addition to streptokinase and aspirin on
early reperfusion and patency in acute myocardial infarction
with ST-elevation. Two previous dose-finding studies with
20 and 76 patients, respectively, have indicated that dalte-
parin at present dosages in combination with streptokinase
might be safe (only minor bleedings and no cerebral
bleedings) (15,22). In another study it was shown that
lmw-heparin given to patients with acute myocardial infarc-
tion starting at day 5 and continuing for 3 weeks after
streptokinase and intravenous standard heparin reduced
cardiac events and also seemed to be safe (16). The golden
standard to show patency is still coronary angiography.
However, indications of early reperfusion can be obtained
by vector-ECG or continuous 12-lead ECG (17,23). An-
other alternative in monitoring frequent blood samples
demonstrates a rapid increase in levels of biochemical
markers (20,21).
In this pilot of trial patients with acute myocardial
infarction treated with streptokinase and aspirin, there was
a tendency of a higher rate of TIMI grade 3 flow in the
infarct-related artery after 24 h in the dalteparin group.
However, in the post-hoc analysis of subgroups of patients
with noninvasive signs of early reperfusion, the improve-
ment of TIMI grade 3 flow at 24 h was statistically
significant which might indicate that dalteparin maintains
patency in the thrombolyzed artery. Furthermore, the indi-
cation of improvement in coronary blood flow was sup-
ported by less postthrombolytic ischemic episodes in the
dalteparin group.
Choice of thrombolytic agent. The benefit with throm-
bolytic treatment is obvious in patients with ST-elevations
or LBBB and onset of symptoms within the last 12 hours.
The choice of fibrinolytic regimen seems to be less impor-
tant for the overall probability of stroke-free survival, as the
fibrin specific regimens that provide more rapid reperfusion
raises the risk of cerebral hemorrhage (24). Thus, the
GUSTO-I trial provided evidence that early and complete
thrombolysis is closely associated with better clinical out-
come and that there was a 14% relative 30-day survival
benefit of t-PA compared with streptokinase (4). However,
in the two previous large scale trials, Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI-2) and International Study of Infarct Survival
(ISIS-3), there were no significant differences between
streptokinase and t-PA in hospital or 35-days mortality
(25,26). As the clinical difference in efficacy between the
different thrombolytic regimes might be considered mar-
ginal in many patients, streptokinase is still widely used
because of the lower cost. If early reperfusion and patency of
streptokinase could be improved by the combination with
adjuvant antithrombotic agents, e.g., lmw-heparin, this
might be an attractive alternative routine treatment as
adjuvant to thrombolysis.
Heparin as adjuvant to thrombolysis. The need for hep-
arin as an adjuvant to thrombolytic treatment is not well
documented. In the short-term perspective, heparin seems
to reduce reocclusion rate of opened infarct-related arteries
(10,27) and especially in combination with t-PA as shown
in Global Utilization of Streptokinase and t-PA for Oc-
cluded Arteries (GUSTO-I) (4). However, the long-term
effects of heparin, intravenous or subcutaneous, in addition
to streptokinase and aspirin are not clear. Available evidence
from clinical trials does not necessitate the routine addition
of heparin to aspirin and streptokinase in acute myocardial
Table 2. Noninvasive Signs of Reperfusion
Placebo Dalteparin n p
Myoglobin, relative increase* 18/45 (40%) 16/52 (31%) 97 0.34
Myoglobin, slope increase† 26/45 (58%) 30/52 (58%) 97 0.99
Vector-ECG‡ 26/33 (79%) 30/43 (70%) 76 0.38
*T90-T0/T0 . 4 (20); †.150 ug/L/h (21); ‡A reduction of STVM, .50 %/120 min or .25%/120 min if STVM was .200
uV or .100 uV (17)
Table 3. TIMI Grade 3 Flow in Infarct-Related Arteries in All Patients and in Subgroups With Noninvasive Signs of Reperfusion
Treated with Placebo versus Dalteparin
TIMI Grade 3 Flow 20–28 h After Start of Thrombolysis
Placebo Dalteparin n p
All patients with angiography 22/43 (51%) 34/50 (68%) 93 0.10
Noninvasive signs of early reperfusion:
Myoglobin, relative increase* 9/18 (50%) 11/13 (85%) 31 0.066
Myoglobin, slope increase† 12/26 (46%) 20/27 (74%) 53 0.038
Vector-ECG‡ 12/23 (52%) 22/30 (73%) 53 0.11
*T90-T0/T0 .4 (20); †.150 ug/L/h (21); ‡A reduction of STVM, .50%/120 min or .25%/120 min if STVM was .200 uV or .100 uV (17)
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infarction (24–26,28). The short-term effect that is seen
during heparin infusion tends to disappear early after
discontinuation because of an increased rate of recurrent
unstable angina, myocardial infarction and urgent interven-
tions. This reactivation phenomenon has been described
early after discontinuation of intravenous heparin, both in
unstable angina (29–31) and after thrombolysis (14).
Therefore, there is no routine using heparin in addition to
streptokinase and aspirin in many countries in northern
Europe which also are in accordance with recent American
treatment guidelines (32).
Hirudin and hirulog are other alternative treatments as an
adjuvant to thrombolysis to improve patency in the infarct-
related artery and clinical outcome in patients with acute
myocardial infarction. The first trials with hirudin and
hirulog showed promising results (33–36). Also, the TIMI
9B and GUSTO IIB trials showed an early reduction of
reinfarctions although this difference was decreased by time
and the bleeding rate was elevated in comparison to heparin
(37,38).
Lmw-heparin. Compared to standard heparin, lmw-
heparin has several advantages, i.e., a longer half-life, a
greater and more predictable bioavailability and no need for
laboratory monitoring. Today there is no doubt that lmw-
heparin is an effective alternative to heparin as prophylactic
of deep vein thrombosis when administered by the subcu-
taneous route (39). Dalteparin had also reduced the rate of
left ventricle thrombosis in post myocardial infarction pa-
tients (40). In the placebo controlled Fragmin during
Instability in Coronary Artery Disease (FRISC) study,
dalteparin twice daily in addition to aspirin reduced the risk
of death and myocardial infarction by more than 50%
compared with aspirin alone during the first five days.
However, early after reduction of the dalteparin dose there
were signs of reactivation (30). In later studies subcutaneous
lmw-heparin has been shown to be at least as effective as
intravenously standard heparin in the acute phase of unsta-
ble coronary disease (41,42).
Lmw-heparin as adjuvant to thrombolysis. Lmw-heparin
might be a convenient alternative to heparin as an adjuvant
to thrombolysis. The effect of lmw-heparin after thrombol-
ysis has so far only been investigated in one published study.
In that trial streptokinase and five days of heparin was given
followed by three weeks of lmw-heparin treatment which
reduced the rate of reinfarction and angina (16). In a recent
dose finding study, it was shown that dalteparin in increas-
ing dosages up to 100 IU/kg subcutaneously twice daily
together with streptokinase gave a rapid rise and dose-
dependent activity of antifactor Xa (15).
In the present study dalteparin was only given twice
before the coronary angiography was performed. During the
dalteparin treatment there were several signs of improve-
ment in coronary blood flow. However, during follow-up
there were eight and two reinfarctions in the dalteparin and
placebo groups, respectively. In five of the eight patients in
the dalteparin group, the reinfarction occurred between
24–72 h after termination of dalteparin suggesting a reac-
tivation of the thrombotic process. There were no differ-
ences in the rate of intervention or death between the two
groups. The treatment was well tolerated and the only side
effect was somewhat more puncture-related bleedings in the
dalteparin group.
Table 4. Postthrombolytic Ischemic STVM Episodes 0–24 Hours and 6–24 Hours in All
Patients and in Subgroups with Noninvasive Signs of Reperfusion
Placebo Dalteparin n p
0–24 hours
All, patients with VCG 13/32 (41%) 11/43 (26%) n 5 75 0.17
Reperfusion signs with Myo* 5/13 (38%) 2/12 (17%) n 5 25 0.38
Reperfusion signs with Myo† 7/18 (39%) 7/24 (29%) n 5 42 0.51
Reperfusion signs with VCG‡ 11/24 (46%) 7/29 (24%) n 5 53 0.10
6–24 hours
All, patients with VCG 12/32 (38%) 7/43 (16%) n 5 75 0.037
Reperfusion signs with Myo* 5/13 (38%) 1/12 (8%) n 5 25 0.16
Reperfusion signs with Myo† 7/18 (39%) 5/24 (21%) n 5 42 0.20
Reperfusion signs with VCG‡ 10/24 (42%) 3/29 (10%) n 5 53 0.01
Myo 5 myoglobin; VCG 5 vector-ECG; *T90-T0/T0 . 4 (20); †.150 ug/L/h (21); ‡A reduction of STVM, .50%/120 min
or .25%/120 min if STVM was .200 uV or .100 uV (17)
Table 5. Clinical Events Until Follow Up Day 21
Placebo
(n 5 47)
Dalteparin
(n 5 54)
Bleeding Total 1 5
Major 0 2
Minor 1 3
Death 6 4
Reinfarction 2 8
Revascularization 12 10
PTCA 8 8
CABG 4 2
Total cardiac events 20 22
Number of patients with
cardiac events
18 15
631JACC Vol. 33, No. 3, 1999 Frostfeldt et al.
March 1, 1999:627–33 Lmw-heparin as Adjuvant to Thrombolysis in Acute MI
Noninvasive indicators of early reperfusion. In previous
studies the rate of TIMI grade 3 flow after 90 min and 24 h
was reported to be about 30% and 50%, respectively, in
patients treated with streptokinase, including those with
spontaneous reperfusion (3,43). This corresponds fairly well
with the 60% TIMI grade 3 flow in the infarct-related artery
after 24 h in the total group of 93 that underwent angiog-
raphy in the present study. The noninvasive sign of reper-
fusion using the relative increase of myoglobin (20) sug-
gested 35% rate of early reperfusion compared to the slope
increase of myoglobin (21) which indicated a higher and
maybe a more realistic rate of early reperfusion (58%), at
90 min. Vector-ECG indicated an optimistic rate of early
reperfusion of 74% after 120 min. Unfortunately no early
coronary angiograms at 90 min were performed, which
make the noninvasive results difficult to validate. Although
the noninvasive indicators of reperfusion are uncertain,
there were no indications of any effects of the lmw-heparin
treatment on early reperfusion. This might be related to the
use of only subcutaneous injections, since a therapeutic level
of antifactor-Xa activity is not reached until around 1–2 h
after the first dose of lmw-heparin (15). In order to explore
possible early benefits of lmw-heparin, an intravenous bolus
dose will be needed.
Limitations. In the present study, lmw-heparin/placebo
treatment was only given twice until the coronary angiog-
raphy was done after 20–28 h. It might have been preferable
to maintain the treatment for a longer time to stabilize the
lesion and the coagulation system in order to avoid the risk
of reactivation. The evaluation of early reperfusion after
90 min would have been more reliable if an early angiog-
raphy was performed, especially as the noninvasive markers
of reperfusion gave variable results. The fact that the
lmw-heparin group had a lower rate of drug treatment,
known hypertension and diabetes at inclusion, indicating a
less severe disease and that there was a higher frequency of
smokers might have influenced the results although the
differences in baseline characteristics between the two
groups were not significant. The very small sample size
implies that this pilot trial should be interpreted cautiously
as the confidence intervals regarding all analyses are wide.
Future and implications. Lmw-heparin might be an at-
tractive, safe, convenient and potent adjuvant treatment to
thrombolysis and aspirin in patients with acute myocardial
infarction. The additive effect of lmw-heparin might con-
tribute to a higher rate of opened infarct-related arteries,
avoid reocclusion episodes and improve maintenance of
coronary blood flow. In future studies prolonged treatment
with the lmw-heparin treatment should be investigated if
late reocclusions and reactivation might be prevented. Fur-
thermore it would probably be advantageous to start with an
intravenous bolus injection to investigate whether lmw-
heparin also might improve early reperfusion. Further larger
studies are needed to evaluate the efficacy of lmw-heparin as
an adjuvant treatment to thrombolysis and aspirin.
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